{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-046719","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2023-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.536146+00:00","generated_at":"2026-06-17T00:49:17.192771+00:00","sec_items":["4.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Aprea Therapeutics dismisses EY, appoints EisnerAmper as new independent auditor","bullets":["On April 17, 2023, Aprea dismissed Ernst & Young LLP as its independent auditor, effective immediately.","The Audit Committee approved the dismissal and engagement of EisnerAmper LLP as new auditor for FY 2023.","EY's reports for 2022 and 2021 contained no adverse opinion or qualification; no disagreements or reportable events existed.","No consultations with EisnerAmper occurred prior to engagement on any accounting matters."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-046719","json":"https://secwatch.observer/filing/0001104659-23-046719.json","markdown":"https://secwatch.observer/filing/0001104659-23-046719.md","text":"https://secwatch.observer/filing/0001104659-23-046719.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465923046719/0001104659-23-046719-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465923046719/tm2312947d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T00:49:17.192771+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d96fcd76952532848bc32b745e8bd5950c293ac","claim":"Aprea Therapeutics, Inc. dismissed Ernst & Young LLP as its auditor.","evidence_excerpt":"On April 17, 2023, Aprea Therapeutics, Inc. (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465923046719/0001104659-23-046719-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"Ernst & Young LLP"},{"label":"Successor","value":"EisnerAmper LLP"}],"fact_type":"auditor_change"},{"claim_id":"bf89fa91acf46723cacf0d49ba219967bb5b3627","claim":"Aprea Therapeutics, Inc. engaged EisnerAmper LLP as its auditor.","evidence_excerpt":"On April 17, 2023, in connection with the Company’s dismissal of EY, the Company engaged EisnerAmper LLP (“EisnerAmper”) as its new independent registered public accounting firm to audit the Company’s financial statements for the year ending December 31, 2023.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465923046719/0001104659-23-046719-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"EisnerAmper LLP"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}